Yeah, the biggest issue this year was the safety data request for 700mg, without that unexpected request from the FDA, we would already be rewarded imo.

The biggest mistake, again imo, was the convertible notes, they I assume they thought they could get to bla submission and good cancer data before they hurt sp, or they assumed these new guys would be as friendly as convertibles before. But that was a mistake which has hurt the sp with the delays, as they needed to raise cash with selling shares while those notes converting has put some downward pressure on the sp, a double whammy.